Table 2.
Table 1b: Cheng 2008
| Methods | Study type | Prospective non-randomized clinical interventional study |
|---|---|---|
| Enrollment method | Consecutive patients with CRVO; patients who agreed to IVS were assigned to the intervention group, while those refusing were assigned to the control group | |
| Inclusion criteria | Clinical evidence of CRVO with intraretinal hemorrhage and dilated, tortuous veins in all 4 quadrants in addition to ME | |
| Exclusion criteria | Not stated | |
| Follow up | Intervention group: 283 ± 70.62 days Control group: 354.05 ± 173.18 days |
|
| Funding source | Not stated | |
| Participants | Country | Kaohsiung, Taiwan |
| Study period | Not stated | |
| No. of eyes | 43 (22 treatment; 21 control) | |
| Baseline characteristics | Not equivalent | |
| Notes | Higher male:female ratio in control group (10:11 versus 9:13); over twice as many ischemic CRVO cases in control group (28.57% of cases versus 13.64% of cases); older age in control group (64.57 ± 8.77 versus 56.45 ± 14.67), and longer follow-up period for control group | |
| Interventions | Treatment | 4 mg (0.1 ml) of triamcinolone acetonide (Kenacort-A; Bristol Myers Squibb, Taipei, Taiwan) |
| Control | Observation (+ PRP for ischemic CRVO cases) | |
| Notes | 6 eyes in the control group were ischemic CRVO cases and received prophylactic PRP to prevent neovascular complications at start of study (3 eyes in study group received prophylactic PRP during follow-up periods); anterior chamber paracentesis performed before all IVS injections; Tobramycin-Tobrex used after all IVS injections | |
| Outcomes | Final mean VA | Intervention: statistically significant increase in VA from 1.00 ± 0.45 logMAR pre-operative to best postoperative VA of 0.67 ± 0.65 logMAR (P = 0.007); 12 eyes (54.5%) improved ≥ 2 Snellen lines during follow-up period Control: no significant increase in VA from 1.04 +/− 0.57 logMAR to 1.11 +/− 0.53 logMAR (P = 0.457) |
| Clinical appearance | Intervention: decline in cotton wool spots, retinal hemorrhage, and ME in all eyes Control: not stated |
|
| ME | Intervention: average decrease of 46.95% in foveal thickness at end of follow up as measured by OCT (P< 0.001) Control: average decrease of 8.33% in foveal thickness at end of follow up as measured by OCT (P = 0.062) |
|
| Complications | Intervention: ME recurrence in 6/22 eyes; 7 eyes (31.82%) had IOP > or = 22 mm Hg (1 trabeculotomy); 1 mature cataract | |
| Subgroup analysis | Intervention: ischemic CRVO cases showed no improvement in VA | |
| Notes | Unclear if measured BCVA in both groups occurred after the 6-month end-point |
BCVA: best corrected visual acuity
CRVO: central retinal vein occlusion
IVS: intravitreal steroids
ME: macular edema
OCT: optical coherence tomography
PRP: panretinal photocoagulation
VA: visual acuity